| (Values in U.S. Thousands) | Jun, 2017 | Jun, 2016 | Jun, 2013 | Jun, 2012 | Jun, 2012 |
| Sales | 26,370 | 17,860 | 22,040 | 23,160 | 19,500 |
| Sales Growth | +47.65% | -18.97% | -4.84% | +18.77% | -80.82% |
| Net Income | -27,350 | -21,510 | -6,260 | -8,310 | -12,310 |
| Net Income Growth | -27.15% | -243.61% | +24.67% | +32.49% | -13,577.78% |
Vernalis Plc S ADR (VNLPY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Vernalis Group plc is a research and development-stage pharmaceutical company based in Oxford, UK, which is developing drugs for the treatment of unmet medical needs such as cancer and inflammatory and infectious diseases. The main technology platform is inhibition of metalloenzymes which will be supplemented through the addition of externally-generated programs.
Fiscal Year End Date: 06/30